SNDX NASDAQ
Syndax Pharmaceuticals, Inc.
1W: +3.3%
1M: -23.4%
3M: -28.8%
YTD: -35.7%
1Y: +1.2%
3Y: +18.9%
5Y: -25.0%
$13.69
+0.47 (+3.56%)
Pre-Market: $13.80 (+0.12, +0.84%)
Weekly Expected Move ±9.2%
$11
$12
$13
$15
$16
Credit Risk of going bust: higher than 66% of companies Debt: 32.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.61 (down 96%), Syndax Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $589.4M against a stock market value of $1.22B.
Distance to default 3.78 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $294.1M (short-term plus half of long-term), stock volatility 51.7%; Altman Z'' -3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.61 (down 96%), Syndax Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $589.4M against a stock market value of $1.22B.
Distance to default 3.78 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $294.1M (short-term plus half of long-term), stock volatility 51.7%; Altman Z'' -3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
At a glance: stocks gapping down premarket
Syndax plummets as IPF asset axatilimab fails in phase 2 trial
What is HC Wainwright’s Estimate for SNDX Q3 Earnings?
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving Average – Here’s What Happened
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
Syndax (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026 - simplywall.st
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - simplywall.st
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?
Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative
A Look At Syndax Pharmaceuticals (SNDX) Valuation As Q1 2026 Results Refocus Investor Attention - simplywall.st
SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell? - MarketBeat
$SNDX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...
Syndax Pharmaceuticals (SNDX) Reports Strong Q1 2026 Earnings an - GuruFocus
Syndax outlines 2026 operating expense target of approximately $400M as Revuforj expands in NPM1
Syndax Pharmaceuticals Q1 Earnings Call Highlights
SNDX Sees Strong Demand Despite Q1 Revenue Miss - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Syndax (NASDAQ: SNDX) details 2026 virtual meeting, director votes and 7.2M-share plan - Stock Titan
Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp - Stock Titan
Syndax (NASDAQ: SNDX) posts 224% Q1 revenue surge and lower loss - Stock Titan
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - ChartMill
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Vanguard Capital Management holds 4.46M shares in Syndax (SNDX) - Stock Titan
Here are the major earnings after the close Thursday
Earnings Scheduled For April 30, 2026
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Brokerages
SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Most and least shorted mid-to mega-cap healthcare stocks in March
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Assenagon Asset Management S.A.
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month High – What’s Next?
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of “Moderate Buy” by Brokerages
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year High – Still a Buy?
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge?
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story?
Syndax (SNDX) Q4 2025 Earnings Call Transcript
Syndax (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Syndax signals expanding Revuforj market share and targets $10B addressable opportunity while ramping Niktimvo
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals GAAP EPS of -$0.78 misses by $0.23, revenue of $68.7M beats by $3.95M
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Syndax Announces Participation in March Investor Conferences
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells $42,930.84 in Stock
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Last Year’s 62.5% Share Price Gain? - Yahoo Finance
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of “Moderate Buy” by Brokerages
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year High – Here’s Why
Syndax Pharma: Continuing Execution In AML
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)